Thorotrast
Updates to Article Attributes
Thorotrast is a suspension of radioactive thorium dioxide first produced in Germany in 1928 and used as a contrast agent until the 1950s. Its principal use was for cerebral angiography: 90% of the estimated 50,000-100,000 patients treated received it for this purpose.
Basic principles
Thorotrast is an alpha emitter and is retained by the body, properties which make it highly carcinogenic. The deposition of Thorotrast is dependent on its radiological use, preparation method, and the age of the preparation. The primary site of deposition is the reticuloendothelial system including the liver, spleen, bone marrow, and lymph nodes.
Radiographic features
In patients treated with Thorotrast, a plain radiograph of the abdomen demonstrates fine, irregular metallic densities distributed throughout the liver, spleen, and peripancreatic lymph nodes 4.
Complications
Hepatic angiosarcoma is the classic Thorotrast-related neoplasm. Other associated cancers include:
-<p><strong>Thorotrast</strong> is a suspension of radioactive thorium dioxide first produced in Germany in 1928 and used as a contrast agent until the 1950s. Its principal use was for <a href="/articles/cerebral-angiography">cerebral angiography</a>: 90% of the estimated 50,000-100,000 patients treated received it for this purpose.</p><h4>Basic principles</h4><p>Thorotrast is an <a href="/articles/alpha-decay">alpha emitter</a> and is retained by the body, properties which make it highly carcinogenic. The deposition of Thorotrast is dependent on its radiological use, preparation method, and the age of the preparation. The primary site of deposition is the reticuloendothelial system including the liver, spleen, bone marrow, and lymph nodes.</p><h4>Radiographic features</h4><p>In patients treated with Thorotrast, a plain radiograph of the abdomen demonstrates fine, irregular metallic densities distributed throughout the <a title="Liver" href="/articles/liver">liver</a>, <a title="Spleen" href="/articles/spleen-1">spleen</a>, and peripancreatic lymph nodes<sup> 4</sup>. </p><h4>Complications</h4><p><a href="/articles/hepatic-angiosarcoma">Hepatic angiosarcoma</a> is the classic Thorotrast-related neoplasm. Other associated cancers include:</p><ul>- +<p><strong>Thorotrast</strong> is a suspension of radioactive thorium dioxide first produced in Germany in 1928 and used as a contrast agent until the 1950s. Its principal use was for <a href="/articles/cerebral-angiography">cerebral angiography</a>: 90% of the estimated 50,000-100,000 patients treated received it for this purpose.</p><h4>Basic principles</h4><p>Thorotrast is an <a href="/articles/alpha-decay">alpha emitter</a> and is retained by the body, properties which make it highly carcinogenic. The deposition of Thorotrast is dependent on its radiological use, preparation method, and the age of the preparation. The primary site of deposition is the reticuloendothelial system including the liver, spleen, bone marrow, and lymph nodes.</p><h4>Radiographic features</h4><p>In patients treated with Thorotrast, a plain radiograph of the abdomen demonstrates fine, irregular metallic densities distributed throughout the <a href="/articles/liver">liver</a>, <a href="/articles/spleen-1">spleen</a>, and peripancreatic lymph nodes<sup> 4</sup>. </p><h4>Complications</h4><p><a href="/articles/hepatic-angiosarcoma">Hepatic angiosarcoma</a> is the classic Thorotrast-related neoplasm. Other associated cancers include:</p><ul>
Unable to process the form. Check for errors and try again.